Clinical Trials Browser

Phase 1 × olaparib × 90 days × Clear all

NCT04633239 2026-03-18

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Phase 1 Recruiting

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT05411094 2026-03-18

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04585958 2026-03-17

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

Phase 1 Recruiting

Neoplasm Metastasis

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT07371104 2026-03-05

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

Phase 1 Recruiting

Neoplasms, Ovarian Neoplasms

NCT02787642 2026-02-25

RADIOSARP

Phase 1 Completed

41 enrolled 15 charts

Sarcoma

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT05238922 2026-02-10

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT06331559 2026-02-09

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumors

NCT06177171 2026-02-02

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Phase 1 Recruiting

BRCA1 Mutation

NCT06560632 2026-01-16

POLAR

Phase 1 Terminated

26 enrolled 14 charts

Other solid neoplasm

Advanced Solid Tumor

NCT00777582 2026-01-13

Phase I Comparative Bioavailability Study

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT06856499 2026-01-09

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Phase 1 Recruiting

Fallopian Tube Neoplasms

NCT03923270 2026-01-08

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02546661 2025-12-29

BISCAY

Phase 1 Active not recruiting

Muscle Invasive Bladder Cancer

NCT06545942 2025-12-23

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03955640 2025-12-22

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Phase 1 Terminated

Breast Neoplasms

NCT01858168 2025-12-19

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

Phase 1 Completed

Rhabdomyosarcoma, Sarcoma, Ewing

NCT04550104 2025-12-19

CONCORDE

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung